Welcome to our dedicated page for Relief Therapeutics Holding SA SEC filings (Ticker: RLFTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Relief Therapeutics Holding SA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Relief Therapeutics Holding SA's regulatory disclosures and financial reporting.
MindMaze Therapeutics Holding files a Form F-6/Fractional ADR form reflecting its name change to MindMaze Therapeutics Holding effective December 1, 2025 and updates the depositary's address to 270 Park Avenue, Floor 8, New York, NY 10017. The form specifies that each ADS represents one (1) ordinary share with a nominal value of CHF 0.10, summarizes issuance, withdrawal, voting, tax and fee mechanics for ADS holders, and describes nominee, disclosure and termination provisions governing the ADR program.